Glicron (Gliclazide)

Glicron is indicated for the treatment of type 2 diabetes mellitus in adults when diet, exercise, and other non‑pharmacologic measures are insufficient to achieve glycemic control.

• Improves fasting and post‑prandial blood glucose levels.
• Can be used as monotherapy in patients newly diagnosed with type 2 diabetes.
• May be combined with other oral antidiabetic agents such as metformin when additional glucose lowering is needed.
• Helps reduce HbA1c when taken consistently as prescribed.
• Is part of individualized treatment plans that include lifestyle modification.
• Provides an option for patients who prefer once‑daily dosing due to its pharmacokinetic profile.

Like other sulfonylureas, Glicron may cause a range of adverse effects, most of which are related to its glucose‑lowering action or to individual patient sensitivity.

Common

• Mild hypoglycemia, especially if meals are skipped or delayed.
• Gastrointestinal discomfort such as nausea, abdominal pain, or dyspepsia.
• Headache or dizziness.
• Weight gain due to increased insulin activity.
• Transient visual disturbances such as blurred vision.
• Mild fatigue or weakness, particularly after dose initiation.

Serious

• Severe hypoglycemia with confusion, loss of consciousness, or seizures.
• Allergic reactions including skin rash, pruritus, or angio‑edema.
• Hematologic abnormalities such as leukopenia or thrombocytopenia (rare).
• Pancreatitis, presenting as upper abdominal pain, nausea, and elevated enzymes (very rare).

When prescribing Glicron, clinicians consider several precautionary factors to minimize risks and ensure safe use in diverse patient populations.

• Assess renal and hepatic function before initiating therapy, as impairment may affect drug clearance.
• Use lower starting doses in elderly patients due to increased sensitivity to hypoglycemia.
• Monitor blood glucose regularly to detect and manage hypoglycemic episodes promptly.
• Avoid use in patients with known hypersensitivity to sulfonylureas or gliclazide.
• Caution in patients with a history of cardiovascular disease, as hypoglycemia can precipitate cardiac events.
• Consider pregnancy and lactation status; the safety profile in these conditions is not well established.
• Review concomitant medications that may potentiate hypoglycemia.

Glicron can interact with other medicines, potentially altering its glucose‑lowering effect or increasing the risk of adverse reactions.

Avoid

• Concurrent use with other sulfonylureas or insulin, which may cause severe hypoglycemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can increase gliclazide plasma concentrations.
• High‑dose aspirin or non‑steroidal anti‑inflammatory drugs that may potentiate hypoglycemic episodes.
• Alcohol consumption, which can potentiate hypoglycemia and impair hepatic metabolism of gliclazide.

Use with caution

• Beta‑blockers, which can mask hypoglycemia symptoms.
• Thiazide diuretics, which may affect glucose metabolism.
• Oral contraceptives or hormone replacement therapy, which can slightly modify gliclazide clearance.
• ACE inhibitors or ARBs, which may require closer glucose monitoring due to possible interaction.